Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States. Over 80% of lung ...

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to GSK’227, now known as risvutatug rezetecan ...

Wendy Brooks, a patient with extensive-stage small cell lung cancer, and her husband and care partner, Larry Brooks, sat down ...

The third generation EGFR TKI targets EGFR mutant NSCLC, showing improved progression free survival and fewer adverse events ...

Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States.Over 80% of lung ...

A Birmingham-based doctor has shared the most "unusual" signs of lung cancer, after revealing it has one of the lowest ...

Key milestone achieved as Company advances clinical program to full approval trial of ateganosine sequenced with a checkpoint inhibitor in ...

Johnson & Johnson's Rybrevant Faspro was approved as a treatment for people with lung cancer by the Food and Drug Administration. Rybrevant Faspro was approved across all indications for subcutaneous ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson has received approval from the U.S. Food and Drug Administration (FDA) for RYBREVANT FASPRO™ (amivantamab ...

In this study, researchers sought to determine the impact of the FDA’s Accelerated Approval pathway among patients with solid tumors.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of one ...

Patient survey finds that those engaged in shared decision-making were 11 times more likely to report higher satisfaction ...